Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar Combined with Ifosfamide + Doxorubicin in First-line Recurrent/Metastatic Soft Tissue Sarcoma
ChiCTR-OIC-17011304Phase 2Recruiting
- Sponsor
- Breast, Bone and Soft Tissue Oncology Department
- Start
- May 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar, doxorubicin and ifosfamide in soft tissue sarcoma (STS), sponsored by Breast, Bone and Soft Tissue Oncology Department. Primary endpoint: Progression-free survival. Started May 2017; status: recruiting.
02
Drugs
endostardoxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR-OIC-17011304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011304.